An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease

Preclinical data have shown that rilmenidine can regulate autophagy in models of Huntington’s disease (HD), providing a potential route to alter the disease course in patients. Consequently, a 2-year open-label study examining the tolerability and feasibility of rilmenidine in mild-moderate HD was u...

Descripción completa

Detalles Bibliográficos
Autores principales: Underwood, Benjamin R., Green-Thompson, Zeyn W., Pugh, Peter J., Lazic, Stanley E., Mason, Sarah L., Griffin, Jules, Jones, P. Simon, Rowe, James B., Rubinsztein, David C., Barker, Roger A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688221/
https://www.ncbi.nlm.nih.gov/pubmed/29075837
http://dx.doi.org/10.1007/s00415-017-8647-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688221/
https://www.ncbi.nlm.nih.gov/pubmed/29075837
http://dx.doi.org/10.1007/s00415-017-8647-0

Ejemplares similares